摘要
目的评价霉酚酸酯(MMF)治疗原发性肾病综合征的效果和安全性。方法运用Cochrane系统评价方法检索Cochrane图书馆、EMBASE、MEDLINE、CBMdisc、CNKI、VIP等电子数据库,检索时间均截止至2006年3月31日,由3名评价员进行资料提取并进行质量评价,对同质资料进行meta分析。结果共纳入3个研究168名患者,2个为完全随机对照研究,1个为半随机对照研究。MMF与来氟米特、盐酸氮芥疗效对比均无统计学意义,而它们之间的副作用对比差别有统计学意义,MMF的副作用发生率低于其他药物。结论MMF是一种较为安全的免疫抑制剂,其疗效并不优于其他免疫抑制剂,但由于纳入的研究质量差,存在着选择性偏倚、测量性偏倚的可能性,有必要进一步开展高质量、大样本随机对照试验评价其疗效和安全性。
Objective To assess the curative effects and safety of mycophenolate mofetil （MMF） in the treatment of primary nephrotic syndrome. Methods Cochrane systematic evaluation was used to search the electric date base such as Cochrane library, EMBASE, MEDLINE, CBMdisc, CNKI and VIP to March 2006, three reviewers extracted data, assessed the quality and had meta - analysis for the results of homogenous studies. Results Three studies involving 168 participants were included, two studies were randomized controlled trials （RCTS）, one study was quasi randomized controlled trial （quasi - RCT）, there were no statistically significant in curative effect between MMF group and control groups, but the side effects in MMF group and control groups were statistically significant, the side effect of MMF was evidently lower than that of other drugs. Conclusion MMF is a safe immunosup- pressive agent to treat the nephrotic syndrome, but its effectiveness is not better than that of other drugs. Due to the bad selection bias and detection bias of studies included, it is necessary to develop the contrast experiment with higher quality, larger scale clinical trials to evaluate its effectiveness and safety.
出处
《中国全科医学》
CAS
CSCD
2006年第24期2009-2014,共6页
Chinese General Practice
关键词
霉酚酸酯
肾病综合征
系统评价
Mycophenolate mofetil
Nephrotic syndrome
Systematic reviews
